

Performance in Delivering Clinical Research - Quarter 4 (2018/2019)

Note: Chelsea and Westminster Hospital NHS Foundation Trust formally acquired West Middlesex University Hospital NHS Foundation Trust on 01/09/2015, and the submission for the former West Middlesex University Hospital NHS Trust has been subsumed into this submission

All hosted, commercial clinical trials closed to recruitment between 01 January 2019 - 31 March 2019

Research Ethics Committee	Integrated Research	Name of Trial	Target Number Of Patients Agreed?	Minimum Number Of Patients Agreed (Enter	Maximum Number Of Patients Agreed (Enter	Target Date To Recruit Patients	Date Agreed to recruit target	Total Number Of Patients Recruited At	Date That The Trial Closed To	Total Number Of Study	Reason For Closure Of Trial	Comments
14/SC/1161	155743	Prospective, single-arm, multi-centre, observational registry to further validate safety and efficacy of the ultimaster DES in real-world patients	Number Agreed	2	2	Not Available / Not Agreed			03/05/2018	2	Recruitment Finished	
17/LO/0012	213544	Clinical safety & efficacy of a new infant formula with specific medical purpose (FSMP) containing 2 human milk oligosaccharides (HMOs)	Range Agreed	1	5	Date Agreed	28/02/2018	0	09/05/2018	0	Recruitment Finished	No eligible patients identified at site.
15/NE/0167	171524	MLN9708 in Multiple Myeloma Not Treated with Stem Cell transplantation - MILLENIUM	Range Agreed	1	2	Not Available / Not Agreed			21/09/2018	0	Withdrawn By Sponsor	One patient consented at site but screening kit expired during screening window and patient did not get enrolled. No other eligible patients were identified before Sponsor closed out site.
17/EM/0157	222140	An International Phase 3 Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study to Evaluate Relugolix Co-Administered with and without Low-Dose Estradiol and Norethindrone Acetate in Women with Heavy Menstrual Bleeding Associated with Uterine Fibroids	Number Agreed	3	3	Not Available / Not Agreed			24/09/2018	0	Withdrawn By Sponsor	Sponsor closed study across whole UK as no patients in UK passed screening.
18/LO/1352	243519	A Phase III/IV, single arm, multicentre study of atezolizumab (Tecentriq) to investigate long-term safety and efficacy in previously-treated patients with locally advanced or metastatic non-small cell lung cancer (TAIL)	Range Agreed	5	8	Not Available / Not Agreed			24/10/2018	5	Recruitment Finished	